In a study by Noroozi et al., MS patients treated with IFNβ experienced a decrease in plasma IL-1β levels as well as the expressions of NLRP3, NLRC4, and AIM2 in peripheral blood mononuclear cells [89]. This evidence concerns the gene IL1B and myeloid sarcoma.